M. Ruiz Martín

The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

O. Mirallas, V. Arrazubi, P. Jiménez-Fonseca, 2023, Therapeutic advances in medical oncology.